Newly appointed CEO Joe Papa outlined his vision for Emergent BioSolutions, which includes winding down two facilities and laying off 300 employees to save $80 million.
According to an AlphaSense transcript on Wednesday’s first-quarter earnings call, Papa said that going forward, the company will focus on its core products such as growing its over-the-counter opioid overdose nasal spray Narcan and its medical countermeasures business. Additionally, a new chief scientific officer position will be created to improve Emergent’s long-term product pipeline, he said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.